This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Beta-only IL-2 ImmunoTherapY Study | MicrobiomeTrials
← Back to trials NCT05086692
A Beta-only IL-2 ImmunoTherapY Study Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2021-08-27Est. Completion: 2026-11-30
Enrollment target: 160 participantsLocations Sharp Memorial Hospital, San Diego, California, United States UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States Providence Saint John's Health Center, Santa Monica, California, United States Boca Raton Regional Hospital, Boca Raton, Florida, United States Emory - Winship Cancer Institute, Atlanta, Georgia, United States Karmanos Cancer Institute, Detroit, Michigan, United States MD Anderson Cancer Center, Houston, Texas, United States Scientia Clinical Research, Randwick, New South Wales, Australia Macquarie University, Sydney, New South Wales, Australia University of the Sunshine Coast, Buderim, Queensland, Australia Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia Princess Margaret Cancer Center, Toronto, Ontario, Canada Mater Misericordiae University Hospital, Dublin, Ireland START Lisbon - Centro de Ensaios Clínicos, ULS Sta Maria, Lisbon, Portugal Instituto Portugues De Oncologia Do Porto, Porto, Portugal Samsung Medical Center, Seoul, Gangnam-gu, South Korea Other microbiome trials you might be interested in Recurrent Breast Carcinoma Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7
This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treat…
Mobile, United States Est. completion Nov 6, 2020
Non-small Cell Lung Cancer
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea
The Catholic University of Korea St. Vincent Hospital, Suwon, Gyeonggi-do, South Korea
Seoul National University Hospital, Seoul, Jongno-gu, South Korea
Institut Catala d'Oncologia (ICO)-Badalona, Badalona, Spain
START Barcelona / HM Nou Delfos, Barcelona, Spain
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hospital Universitario Ramón y Cajal, Madrid, Spain
START Madrid / Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
Hospital Universitario Hm Sanchinarro, Madrid, Spain
Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain
Hospital Universitario de Torrejon, Torrejón, Spain
Hautkrebszentrum, Dermatologische Klinik Universitätsspital Zürich, Zurich, Switzerland This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participa…
Bakersfield, United States Est. completion Jan 24, 2028
Malignant Pleural Mesothelioma, Advanced
This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combinati…
Shanghai, China Est. completion Nov 30, 2028